More than 400 cartons of Nilotinib capsules were voluntarily recalled by Cipla USA after failing manufacturing specifications ...

Cipla USA, a subsidiary of the Indian drugmaker, is recalling over 400 cartons of generic anti-cancer drug Nilotinib due to a manufacturing issue. The recall is classified as Class III by the USFDA, ...

Cipla USA is recalling over 400 cartons of its anti-cancer drug Nilotinib Capsules. The recall is due to a manufacturing issue where the capsules failed to meet specifications. This is a voluntary ...

Cipla USA is voluntarily recalling over 400 cartons of its anti-cancer drug, Nilotinib Capsules, due to a manufacturing issue.

A US-based subsidiary of Cipla has recalled more than 400 cartons of a generic anti-cancer medication from the American market after a manufacturing-related issue was detected, according to the US ...

Al-Aly and his colleagues found that people starting the GLP-1 drugs had lower risks of developing addiction to multiple ...

Cipla recalls over 400 cartons of Nilotinib cancer medication in the U.S. due to manufacturing specification issues, USFDA reports.

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

Cipla USA recalls Nilotinib Capsules in the US due to manufacturing issues. USFDA Enforcement Report details the Class III voluntary recall.

TD Cowen 46th Annual Health Care Conference March 4, 2026 10:30 AM ESTCompany ParticipantsBrian Sullivan - Co-Founder, Chairman ...

LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 –– Reduced secured and convertible debt by 90% from ...